Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of 10% in its most recent quarter. The company continues to focus on cutting ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the ...

Pfizer Inc (NYSE:PFE) maintains global operations across medicines and vaccines, delivering consistent earnings, operational ...

Pfizer’s commitment to returning capital to shareholders is evident in its current annual dividend of $1.72 per share. This translates to a quarterly payment of $0.43 per share. As of May 22, 2025, ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Pfizer stands as one of the largest pharmaceutical companies in the world. Although it has an attractive 7.1% yield, it has a big blemish in its dividend past. Investors looking at drug stocks would ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds.